TenCure

Cancer Drug Development

Health Tech & Life Sciences
Non Active, Mar 2020 ceased to operate
Pre-Funding Jerusalem, Israel Founded 2012
Website ↗
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2012
Headcount
6
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

TenCure is a biopharmaceutical company developing personalized oncology therapeutics for epithelial solid tumors associated with skin, colon, and pancreatic cancer. TenCure is establishing a first-in-class, diverse pipeline of oncology therapies, with a specific focus on niche markets with unmet needs. The company has identified a new mechanism of action by which the insulin signaling pathway affects cancer formation and progression. TenCure is developing inhibitory agents within the insulin signaling pathway that deactivate these targets. The drug candidates have the potential to inhibit cancer cell proliferation, eradicate tumors, and suppress malignant tumor progression. TenCures drug candidates provide the basis for the development of novel cancer therapies addressing various solid cancer indications that are resistant to current treatment modalities. The companys management team has developed a plan aimed at shortening the development path, reducing costs, and increasing the likelihood of bringing a mature product to advanced clinical trials within three years.

Q&A

What is TenCure's primary focus in drug development?
TenCure is a biopharmaceutical company focused on developing personalized oncology therapeutics for epithelial solid tumors, including skin, colon, and pancreatic cancer.
What is the core mechanism of action TenCure is exploring for cancer treatment?
TenCure has identified a new mechanism of action involving the insulin signaling pathway's effect on cancer formation and progression. The company is developing inhibitory agents to deactivate targets within this pathway.
What is the current status of TenCure?
TenCure is currently inactive and ceased to operate in March 2020.
When was TenCure founded?
TenCure was founded in September 2012.
How many employees did TenCure have?
TenCure had an employee count in the 1-10 range.
What is TenCure's primary sector classification?
TenCure's primary sector classification is Health Tech & Life Sciences.
Does TenCure hold any patents?
Yes, TenCure holds one patent.
What is the current product stage of TenCure's developments?
TenCure's product stage is R&D.

Team · 1

Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2B2C

Highlights

1 Patents

Tags

obesitydiabetesoncologytargeted-therapypharma-companiestherapeuticscancerpersonalizationbiopharmaceuticaldrug-discoverypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitetencure.co.il/

Identifiers & details

Founded2012-9
Employees (exact)6
Status reasonNon Active, Mar 2020 ceased to operate